Organon & Co. 10-Q Summary: Q2 2025
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Organon & Co. is a global healthcare company focused on women's health and general medicines, operating as a single segment with U.S. and International reporting units. The company manages a portfolio of over 70 products, including key brands such as Nexplanon, Follistim AQ, and Vtama.
Key Financial Metrics
| Metric ($ millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenues | 1,594 | 1,607 | 3,107 | 3,229 |
| Gross Profit | 874 | 939 | 1,715 | 1,896 |
| Gross Margin | 54.8% | 58.4% | 55.2% | 58.7% |
| Net Income | 145 | 195 | 232 | 396 |
| Diluted EPS | $0.56 | $0.75 | $0.89 | $1.53 |
| Operating Cash Flow (YTD) | 295 | 408 | — | — |
| Cash & Equivalents | 599 | — | — | — |
| Total Debt (Principal) | 8,896 | — | — | — |
Note: Q2 2024 figures are provided for comparison; YTD figures represent the six months ended June 30.
Material Changes vs. Prior Period
- Revenue Decline: Worldwide sales decreased 1% in Q2 and 4% YTD compared to 2024. This was driven by Loss of Exclusivity (LOE) impacts on Atozet (down 38% in Q2) and Singulair (down 29% in Q2), partially offset by growth in Vtama, Hadlima, and Follistim AQ.
- Profitability Pressure: Net income fell 26% in Q2 and 41% YTD. Gross margins contracted due to unfavorable product mix, price impacts, and increased amortization from the Dermavant acquisition.
- Restructuring Costs: The company incurred $88 million in restructuring costs YTD 2025 (vs. $23 million in 2024) related to a ~6% headcount reduction to optimize the operating model.
- Debt Management: Organon repurchased $242 million of its 5.125% notes due 2031, recognizing a $42 million pre-tax gain. Total debt principal remains high at $8.9 billion.
Outlook, Risks, and Unusual Items
- Acquisitions & Milestones: The company acquired U.S. rights to Tofidence from Biogen (upfront payment of $51 million) and continues to integrate Dermavant. Significant contingent consideration liabilities exist, with potential future milestone payments totaling up to $2.6 billion.
- Legal Contingencies: Organon faces ongoing product liability litigation regarding Fosamax (femur fractures) and Nexplanon/Implanon. A Master Settlement Agreement was signed in July 2025 for New Jersey Fosamax claims for a confidential, non-material sum. The company has no insurance for most product liabilities.
- Regulatory & Tax: The "One Big Beautiful Bill Act" (OBBBA) was signed into law in July 2025, introducing changes to interest deductibility and R&D expensing. Organon is evaluating the impact on its tax provision.
- Patent Challenges: Organon is defending patents for Nexplanon against a generic application by Xiromed, which could impact exclusivity in 2027.
- Dividends: The quarterly dividend was reduced to $0.02 per share in Q2 2025 (down from $0.28 in Q2 2024).
Investor Verification Checklist
- LOE Impact Trajectory: Verify the duration and magnitude of sales declines for Atozet and Singulair as generic competition matures in key markets (France, Spain, Japan).
- Restructuring Savings: Confirm the realization of the projected $200 million in annual savings from the current restructuring initiatives.
- Debt Covenants: Monitor compliance with the Senior Credit Agreement's leverage ratio covenant given the high debt load and recent restructuring charges.
- Legal Exposure: Assess the potential financial impact of the Fosamax litigation in California and other jurisdictions not covered by the New Jersey settlement.
- Acquisition Integration: Evaluate the commercial ramp-up of Vtama (atopic dermatitis indication) and Tofidence to offset legacy product declines.